NanoViricides Files Quarterly Report Highlighting Broad-Spectrum Antiviral Candidate NV-387

NanoViricides, Inc. has filed its Form 10-Q for the quarter ended September 30, 2025, providing significant updates on its lead drug candidate NV-387. The company detailed progress on this first-in-class broad-spectrum antiviral designed to resist viral escape by mimicking conserved sulfated proteoglycan receptors used by more than 90% of viruses. This innovative mechanism represents a potential breakthrough in antiviral therapy, addressing a critical gap in current treatment options.

The company noted that NV-387's mechanism may address major unmet needs across multiple viral diseases, including Influenza strains prone to rapid resistance, Respiratory Syncytial Virus (RSV), Measles, MPox, and gaps in existing Smallpox countermeasures. This broad-spectrum approach could revolutionize how viral infections are treated, particularly given the limitations of current antiviral medications that often lose effectiveness as viruses evolve resistance. The company's technology platform and programs are detailed on their corporate website at https://www.nanoviricides.com.

Current concerns highlighted in the report include the dominant A/H3N2 clade K variant and a mismatched seasonal vaccine with historically low efficacy, underscoring the urgent need for antiviral solutions that maintain effectiveness as viruses evolve. This addresses a critical challenge in infectious disease management where viral mutations frequently outpace vaccine development and render existing treatments less effective over time.

NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials. The company plans to develop this candidate as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. This development pathway represents a comprehensive approach to addressing multiple viral threats with a single therapeutic platform.

The company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms for the treatment of numerous viral diseases including Human Immunodeficiency Virus, Hepatitis B and C, Rabies, Herpes Simplex Virus, Influenza, Dengue viruses, and certain Coronaviruses.

As a clinical stage company creating special purpose nanomaterials for antiviral therapy, NanoViricides represents an innovative approach to drug development. The nanoviricide class of drug candidates and technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections.

The development of NV-387 and the company's broader antiviral platform could have significant implications for global public health. By targeting conserved viral receptors rather than specific viral proteins, this approach potentially offers protection against a wide range of current and emerging viral threats. This technology could provide a crucial tool in pandemic preparedness and response, particularly given the increasing frequency of viral outbreaks and the limitations of current targeted therapies.